Prognostic value of day 14 blast percentage and the absolute blast index in bone marrow of children with acute lymphoblastic leukemia

Simple item page
dc.contributor.authorVisser J.H.
dc.contributor.authorWessels G.
dc.contributor.authorHesseling P.B.
dc.contributor.authorMmed I.L.
dc.contributor.authorOberholster E.
dc.contributor.authorMansvelt E.P.G.
dc.date.accessioned2011-05-15T16:17:37Z
dc.date.available2011-05-15T16:17:37Z
dc.date.issued2001
dc.description.abstractThe product of the percentage blasts on the bone marrow aspirate (BMA) and the biopsy cellularity has been tarmed the "absolute blast index aspirate" (ABI-aspirate) and is used to measure disease response on day 7 of induction therapy. The authors compared the event-free survival (EFS) in high-risk and standard-risk patients as identified by the ABI-aspirate and the BMA percentage blasts on day 14 of induction therapy. Both indices identified high-risk cases. EFS of patients categorized as high-risk by these 2 methods and the high-risk criteria used by the authors' service (WCC of > 20 × 109/L, age < 2 and > 8 years and a peripheral blood blast count of > 1.0 × 109/L on day 8 of induction) did not differ. There was concordance between patients identified as high risk by all 3 methods. The results confirmed the prognostic value of the ABI-aspirate and the BMA percentage blasts on day 14 of induction therapy, but these methods were not superior to the high-risk criteria currently in use.
dc.description.versionArticle
dc.identifier.citationPediatric Hematology and Oncology
dc.identifier.citation18
dc.identifier.citation3
dc.identifier.issn08880018
dc.identifier.other10.1080/08880010151114804
dc.identifier.urihttp://hdl.handle.net/10019.1/14295
dc.subjectacute lymphoblastic leukemia
dc.subjectadolescent
dc.subjectarticle
dc.subjectblast cell
dc.subjectbone marrow biopsy
dc.subjectbone marrow examination
dc.subjectcancer survival
dc.subjectchild
dc.subjectfemale
dc.subjecthigh risk patient
dc.subjecthuman
dc.subjectinfant
dc.subjectmale
dc.subjectprognosis
dc.subject6-Mercaptopurine
dc.subjectAdolescent
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectAsparaginase
dc.subjectBiopsy, Needle
dc.subjectBlast Crisis
dc.subjectBone Marrow
dc.subjectChild
dc.subjectChild, Preschool
dc.subjectCyclophosphamide
dc.subjectCytarabine
dc.subjectDaunorubicin
dc.subjectDisease-Free Survival
dc.subjectEthnic Groups
dc.subjectFemale
dc.subjectFollow-Up Studies
dc.subjectHumans
dc.subjectInfant
dc.subjectLeukemia, Lymphocytic, Acute
dc.subjectMale
dc.subjectMethotrexate
dc.subjectPredictive Value of Tests
dc.subjectPrednisone
dc.subjectPrognosis
dc.subjectRecurrence
dc.subjectRisk Assessment
dc.subjectSouth Africa
dc.subjectSurvival Rate
dc.subjectTime Factors
dc.subjectVincristine
dc.titlePrognostic value of day 14 blast percentage and the absolute blast index in bone marrow of children with acute lymphoblastic leukemia
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Tygerberg Hospital Publications